Kenneth Galbraith, Chair & CEO at Zymeworks Inc. (ZYME), sold 47,808 shares at $11.22 ($516K) on 2024-01-08, disclosed to the SEC on 2024-01-08.
Open-market sale of $516k ZYME by Chair & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.65 | 18,198 | $194K | 37.6% |
| 2 | $10.65 | 18,198 | $194K | 37.6% |
| 3 | $11.22 | 5,706 | $64K | 12.4% |
| 4 | $11.22 | 5,706 | $64K | 12.4% |
| Total | $10.79 avg | 47,808 | $516K | 100% |
| Filing → |
| ZYME | SELL | 2025-12-22 | $2.6M | — | Filing → |
| ZYME | SELL | 2025-01-06 | $1.7M | — | Filing → |
| MGNX | SELL | 2020-09-10 | $1.1M | — | Filing → |